Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Mink Therapeutics Inc

INKT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$12.20

▲ +4.99%

Market Cap $62.26M · Vol 2.49K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$62.26M

Micro Cap

Div Yield

N/A

EPS Growth

+6.31%

YoY

RSI (14)

64.27

Momentum

Beta

0.47

vs Market

52W High

$16.91

27.85% below

52W Low

$8.55

42.69% above

Volume

2.49K

Avg 2.04K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

40.80%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Mink Therapeutics Inc (INKT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does INKT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+8.25%

+10.21%

+11.52%

+7.11%

YTD

+9.42%

-18.39%

-26.06%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-12,494,260.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-125.20% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	N/A
P/FCF	N/A
EPS Growth	+6.31%
Outstanding Shares	5.10M

Technical Indicators

50-Day SMA	$11.31
200-Day SMA	$11.45
RSI (14)	64.27
Beta	0.47
52-Week High	$16.91
52-Week Low	$8.55

Volume Today	2.49K
Avg Daily Volume (30D)	2.04K
Relative Volume	1.22x
Volatility (10D)	55.89
Volatility (30D)	55.27
Free Float	40.80%

Analyst Consensus

BUY

Current Price $12.20

Mean Target $39.00

52W Low$8.55 52W High$16.91

Current

Target

$8.55 $16.91

Current Analyst target

+219.67% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG012J84WM7

ISINUS6036932019

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.09% ONC BeOne Medicines AG +1.44% RVMD Revolution Medicines Inc -1.07% 068270.KS Celltrion Inc -0.93% ABVX Abivax SA -2.75%

Company Profile

MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.